Brief: Equillium Announces Positive Topline Data From Type B Portion Of Phase 1b EQUALISE Study Of Itolizumab In Lupus Nephritis

Equillium

01/04/2024 15:28

April 1 (Reuters) - Equillium Inc  EQ.O :
    * EQUILLIUM ANNOUNCES POSITIVE TOPLINE DATA FROM THE TYPE B
PORTION OF THE PHASE 1B EQUALISE STUDY OF ITOLIZUMAB IN LUPUS
NEPHRITIS
    * EQUILLIUM INC: MORE THAN 80% OF SUBJECTS ACHIEVED >50%
REDUCTION
IN URINE PROTEIN CREATININE RATIO (UPCR)
    * EQUILLIUM INC: ITOLIZUMAB DEMONSTRATED A FAVORABLE SAFETY
AND
TOLERABILITY PROFILE

Source text for Eikon:  ID:nBwbL4gxna 
Further company coverage:  EQ.O 

 ((Reuters.Briefs@thomsonreuters.com;))